CA-SCIENTIST.COM
18.6.2024 13:56:30 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that LIDE Biotech has successfully completed VERIF.i® on-site assessments at two of its China-based facilities—Shanghai and Xi’an. VERIF.i is Scientist.com’s on-site pre-assessment program that helps suppliers of regulated services demonstrate the quality and standards of their laboratories to both existing and prospective clients.
LIDE is an award-winning, translational medicine contract research organization (CRO) with over a decade of experience delivering preclinical drug evaluation services globally. In addition to offering innovations in oncology translational research and immune-oncology, LIDE has a collection of over 2,000 patient derived xenograft (PDX) models covering 50+ cancer types, of which 200+ are special drug resistant and/or genetically altered. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment.
“We’ve adopted the highest global operational standards at LIDE, ensuring our facilities and processes not only meet but surpass industry expectations,” stated Dr. Danyi Wen, President and CEO of LIDE Biotech. “VERIF.i is one more way to demonstrate our commitment to quality and compliance to our biotech and pharmaceutical clients globally.”
VERIF.i provides LIDE Biotech and other suppliers of regulated research services, including human biospecimen acquisition, animal studies and chemistry, manufacturing and controls (CMC) services, the opportunity to proactively communicate the quality and capabilities of their laboratories against pre-defined criteria developed specifically for the biopharma industry. Independent, third-party auditors carry out on-site inspections, the results of which can be shared with clients or used to improve lab operations.
“On-site assessments of laboratories have always been difficult to complete due to high costs and intensive resource and time requirements,” stated Matt McLoughlin, SVP of Categories and Compliance at Scientist.com. “VERIF.i provides a new and viable solution for marketplace sellers and buyers alike. It enables a high-quality supplier like LIDE to differentiate itself from its peers by sharing information about its facilities, personnel and processes. At the same time, it eliminates redundant work and ultimately saves both buyers and sellers time and money."
VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/
About LIDE Biotech
LIDE biotech is committed to accelerating translation from pre-clinical to clinical for our clients. Our robust database of over 2000+ PDX, CDX, and cell line models is an industry-leading resource. Additionally, LIDE provides proprietary kits (small sample K-cell collection, conditional cell reprogramming, MiniPDX and IO-FIVE assays) that help clients streamline their studies. Most importantly, our hospital collaborations offer clients an unparalleled translational platform to leverage in their drug R&D journey. Our CRO services can be custom tailored or leveraged with out-of-the-box solutions, including in vitro and in vivo studies, 3D and organoid approaches, all supplemented with in-house bioinformatics and a parallel immuno-oncology platform.
Visit www.lidebiotech.com to learn more and follow updates on the LIDE Biotech LinkedIn page.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 5,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618429370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom